Company news: Medivation/Astellas and Teva

Share this article:
The FDA is set to give the Medivation/Astellas drug enzalutamide the once-over on November 22. The daily medication is for castration-resistant prostate cancer for patients who have previously undergone docetaxel-based chemotherapy. The FDA accepted the new drug application under a priority review designation.

Teva is kicking off a third Phase III trial of experimental relapsing MS drug, laquinimod, the firm said. The company, along with partner Active Biotech, said in a statement Wednesday that the daily oral medication will be tested in a 24-month trial of about 1,800 patients. The trial will be used to test a 0.6-mg dose and a 1.2-mg dose. An oral treatment could be a big deal in the space, for injections and infusions are the most common forms of medical treatments for the degenerative disease of the central nervous system. But Teva's R&D program trails other players, including Biogen Idec's BG-12, now awaiting FDA approval, and Novartis' Gilenya, which has had a slow launch. The new Phase III trial, CONCERTO, follows the completed ALLEGRO and BRAVO Phase III studies. Laquinimod is also in Phase II tests for treating Crohn's disease and lupus.
Share this article:

Email Newsletters

More in Business Briefs

Panel votes against painkiller

Panel chair Randall Flick said QRxPharma "had not provided sufficient evidence to support a claim that Moxduo is safer than morphine or oxycodone."

Amgen sales rose by 5% in Q1

But demand for Enbrel and Aranesp slipped.

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.